Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting
Portage Biotech Inc. (NASDAQ: PRTG) announced that preclinical data regarding its STING-activating therapy, PORT-5 (STI-001), will be presented at the AACR 2022 Annual Meeting in New Orleans from April 8-13, 2022. The therapy aims to enhance anti-tumor responses and overcome challenges in clinical delivery of STING therapies. CEO Dr. Ian Walters expressed gratitude for the research's inclusion in a late-breaking session, indicating its significance in advancing cancer treatment. Portage collaborates with Stimunity and the Institut Curie for this development.
- Preclinical data presentation at a prominent conference (AACR 2022) enhances visibility.
- Innovative approach with PORT-5 potentially positions the company as a leader in STING therapies.
- Collaboration with Stimunity and Institut Curie may provide strategic advantages and resources.
- Forward-looking statements highlight inherent risks and uncertainties in therapy development.
Preclinical data will be presented in a late-breaking abstract session
WESTPORT, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, and Stimunity, an early-stage biotech company focused on the development of a unique STING agonist based on virus-like particles, today announced data from a collaboration on a STING-activating therapy, PORT-5 (STI-001) will be presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting taking place April 8-13, 2022, in New Orleans, Louisiana.
“The stimulator of interferon genes (STING) pathway is a well-recognized immune-boosting pathway and has long been an area of interest in cancer treatment, but STING-activating therapies have historically been limited in clinical trials due to delivery challenges,” said Dr. Ian Walters, chief executive officer of Portage. “We are grateful that the scientific committee found the research on our systemically delivered STING-based therapy, PORT-5, to be highly significant and timely to be included in the late-breaking session for AACR and look forward to sharing further updates in the coming months.”
Presentation Details
Abstract Title: Cellular selectivity of STING stimulation determines priming of anti-tumor T cell responses
Abstract Number: 7829
Presenter: Bakhos Jneid, Institut Curie
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Session Date/Time: April 13, 2022, 9:00am – 12:30pm CT
Location: Poster Section 16
About Portage Biotech Inc.
Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.
About PORT-5 (STI-001)
PORT-5 offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist in a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to specific cells. The therapy can be administered systemically yet stimulates a targeted and specific immune activation. One or more targeted agents can be packaged within the VLP to enhance its potency. PORT-5 is currently in preclinical studies and is being advanced in collaboration with Stimunity and the Institut Curie.
Forward-Looking Statements
This news release contains statements about the Company’s information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
Chuck Padala
chuck@lifesciadvisors.com
Media Relations
Gwen Schanker
gschanker@lifescicomms.com
FAQ
What new data is Portage Biotech presenting at AACR 2022?
When will Portage Biotech's presentation at AACR 2022 take place?
What is the significance of PORT-5 (STI-001) in cancer treatment?
Who is collaborating with Portage Biotech on PORT-5?
What potential risks are associated with Portage Biotech's forward-looking statements?
